For the treatment of breast cancer, the biggest newsmaker at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago had nothing to do with drug development. Instead, the findings came from a National Cancer Institute (NCI)-sponsored study directing physicians to use less treatment, not more, in most women with a common form of early stage disease.